Search Results

25 results

  1. CROM Symposium, Online, 2020, CROM 01

    A consortium approach for consumer-reported outcome measures for assessing tobacco and nicotine-containing products

    ACQUADRO C.(1); AFOLALU E.F.(2); BLACK R.A.(3); CAHOURS X.(4); CHREA C.(2); CLERC E.(2); CURTIN G.(5); EVANS S.(6); GILES L.(7); MacCAFFREY S.(3); PARK H.(8); PRASAD K.(9); SARKAR M.(10); SHIFFMAN S.(11); WEI Lay(10)
    (1) ICON PLC, Lyon, France; (2) Philip Morris Products SA, Switzerland; (3) JUUL Labs, Inc., USA; (4) Imperial Brands, France; (5) RAI Services Company, USA; (6) Turning Point Brands, USA; (7) JT International SA, Switzerland; (8) KT&G Research Institute, Republic of Korea; (9) British American Tobacco, U.K.; (10) Altria Client Services, USA; (11) Pinney Associates, USA
    The continuum of risk of tobacco products is generally accepted among public health authorities, where combustible products like cigarettes are the most risky and noncombustible products are at the lower end of the continuum. Adult smokers (AS)...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 44

    Lung biomarkers of harm/effect for tobacco regulatory research: opportunities and challenges – a literature review

    MAKENA P.(1); EDMISTON J.(2); BEATTIE E.(3); MASON E.(4); McEWAN M.(5); PRASAD K.(5)
    (1) RAI Services Company, Winston-Salem, NC, U.S.A.; (2) Altria Client Services LLC, Richmond, VA, U.S.A.; (3) Cliantha Research Limited, Canada; (4) Imperial Brands PLC, Bristol, U.K.; (5) British American Tobacco (Investments) Limited, Southampton, U.K.
    Biomarkers of potential harm (BoPH) are indicators of biological perturbations in response to smoking, which may contribute to smoking-related disease. In this review, a project of the CORESTA Biomarkers Sub-Group, we critically assessed the...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 13 (also presented at TSRC 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 1. Mouse lymphoma assay

    LEVERETTE R.(1); THORNE D.(2); BREHENY D.(2); FOWLER K.(1); McENANEY S.(3); LLOYD M.(3); CLEMENTS J.(3); BOMBICK B.(1); GACA M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) British American Tobacco (Investments) Ltd., Southampton, U.K.; (3) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    In vitro studies have been widely used to support the toxicological evaluation of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from different tobacco and nicotine delivery products was assessed...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 14 (also presented at TSRC 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 2. In Vitro micronucleus assay

    LEVERETTE R.(1); THORNE D.(2); BREHENY D.(2); FOWLER K.(1); McENANEY S.(3); WHITWELL J.(3); CLEMENTS J.(3); BOMBICK B.(1); GACA M.(2)
    (1) RAI Services Company, Scientific & Regulatory Affairs, Winston-Salem, NC, U.S.A.; (2) British American Tobacco (Investments) Ltd., Southampton, U.K.; (3) Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    In vitro studies have been widely used to support toxicological evaluations of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from tobacco and nicotine delivery products were assessed against a 3R4F...
  9. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 014 (also presented at CORESTA 2018)

    Genotoxicity evaluation of tobacco and nicotine delivery products: Part 1. Mouse lymphoma assay

    LEVERETTE R.(1); BOMBICK B.(1); FOWLER K.(1); BREHENY D.(2); GACA M.(2); THORNE D.(2); CLEMENTS J.(3); LLOYD M.(3); McENANEY S.(3)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) British American Tobacco (Investments) Ltd., Southampton, UK; (3) Covance Laboratories Ltd, Harrogate, UK
    In vitro studies have been widely used to support the toxicological evaluation of chemicals and complex mixtures including cigarette smoke. In this study a variety of test matrices from different tobacco and nicotine delivery products was assessed...